BRPI0513840A - método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento - Google Patents
método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamentoInfo
- Publication number
- BRPI0513840A BRPI0513840A BRPI0513840-0A BRPI0513840A BRPI0513840A BR PI0513840 A BRPI0513840 A BR PI0513840A BR PI0513840 A BRPI0513840 A BR PI0513840A BR PI0513840 A BRPI0513840 A BR PI0513840A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- need
- mammalian patient
- treating
- control
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 19
- 238000000034 method Methods 0.000 title abstract 15
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 9
- 208000008589 Obesity Diseases 0.000 title abstract 7
- 235000020824 obesity Nutrition 0.000 title abstract 7
- 201000001421 hyperglycemia Diseases 0.000 title abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 3
- 208000017170 Lipid metabolism disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 208000006575 hypertriglyceridemia Diseases 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 208000035150 Hypercholesterolemia Diseases 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 abstract 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 abstract 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 abstract 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229930014669 anthocyanidin Natural products 0.000 abstract 1
- 235000008758 anthocyanidins Nutrition 0.000 abstract 1
- 229930002877 anthocyanin Natural products 0.000 abstract 1
- 235000010208 anthocyanin Nutrition 0.000 abstract 1
- 239000004410 anthocyanin Substances 0.000 abstract 1
- 150000004636 anthocyanins Chemical class 0.000 abstract 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 abstract 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 abstract 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 abstract 1
- 229940096998 ursolic acid Drugs 0.000 abstract 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
MéTODO PARA CONTROLE DE OBESIDADE EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO, MéTODO PARA TRATAMENTO DE OBESIDADE EM UM PACIENTE HUMANO DIABéTICO E SENDO TRATADO COM UMA DROGA RECEITADA PARA DIABETES, MéTODO PARA TRATAMENTO DE DIABETES MELLITUS EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO PARA CONTROLE DA DIABETES MELLITUS, MéTODO PARA TRATAMENTO OU CONTROLE DE HIPERGLIPICEMIA EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO, COMPOSIçãO PARA USO NO TRATAMENTO DE OBESIDADE, DIABETES, OU HIPERGLICEMIA COMO DOENçA, MéTODO PARA TRATAMENTO OU CONTROLE DE DISTúRBIOS LIPìDICOS,HIPERLIPEDEMIA, OU BAIXO NìVEL DE HDL EM UM PACIENTE MAMìFERO NECESSITADO DO MESMO, MéTODO PARA TRATAMENTO OU CONTROLE DE HIPERCOLESTEROLEMIA EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO, MéTODO PARA TRATAMENTO OU CONTROLE DE HIPERGLICERIDEMIA EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO, MéTODO PARA TRATAMENTO OU CONTROLE DE DISLIPIDEMIA E/OU BAIXO NìVEL DE HDL COLESTEROL EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO, E MéTODO PARA TRATAMENTO DE ARTERIOSCLEROSE EM UM PACIENTE MAMìFERO NECESSITADO DE UM TAL TRATAMENTO Trata-se de um método para tratamento de obesidade, diabetes, níveis altos de colesterol e doenças associadas incluindo hiperglicemia, distúrbios lipídicos, hipergilceridemia, dislipidemia e arteriosclerose em mamíferos mediante utilização de antocianinas, antocianidinas, ácido ursólico e/ou ácido betulínico. São igualmente descritas composições adaptadas para estes tratamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59180604P | 2004-07-29 | 2004-07-29 | |
| US11/072,151 US7772195B2 (en) | 2004-07-29 | 2005-03-04 | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| PCT/US2005/026220 WO2006031293A2 (en) | 2004-07-29 | 2005-07-25 | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513840A true BRPI0513840A (pt) | 2008-05-20 |
Family
ID=35733130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513840-0A BRPI0513840A (pt) | 2004-07-29 | 2005-07-25 | método para controle de obesidade em um paciente mamìfero necessitado de um tal tratamento, método para tratamento de obesidade em um paciente humano diabético e sendo tratado com uma droga receitada para diabetes, método para tratamento de diabetes mellitus em um paciente mamìfero necessitado de um tal tratamento para controle da diabetes mellitus, método para tratamento ou controle de hiperglicemia em um paciente mamìfero necessitado de um tal tratamento, composição para uso no tratamento de obesidade, diabetes, ou hiperglicemia como doença, método para tratamento ou controle de distúrbios lipìdicos, hiperlipidemia, ou baixo nìvel de hdl em um paciente mamìfero necessitado do mesmo, método para tratamento ou controle de hipercolesterolemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de hipergligeridemia em um paciente mamìfero necessitado de um tal tratamento, método para tratamento ou controle de dislipidemia e/ou baixo nìvel de hdl colesterol em um paciente mamìfero necessitado de um tal tratamento, e método para tratamento de arteriosclerose em um paciente mamìfero necessitado de um tal tratamento |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7772195B2 (pt) |
| EP (1) | EP1771188A4 (pt) |
| JP (1) | JP2008508284A (pt) |
| AU (1) | AU2005285463B2 (pt) |
| BR (1) | BRPI0513840A (pt) |
| CA (1) | CA2573539A1 (pt) |
| MX (1) | MX2007000679A (pt) |
| NZ (1) | NZ552395A (pt) |
| RU (1) | RU2359689C2 (pt) |
| WO (1) | WO2006031293A2 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772195B2 (en) * | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| BRPI0605693B8 (pt) * | 2006-12-15 | 2021-05-25 | Ache Laboratorio Farm S/A | processo para preparação de um produto farmacêutico ou veterinário padronizado a partir das cascas dos frutos de plantas do gênero vitis |
| US20090176718A1 (en) * | 2007-10-31 | 2009-07-09 | David Ribnicky | Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome |
| US20100311801A1 (en) * | 2007-12-20 | 2010-12-09 | Reiner Fischer | Use of tetramic acid derivatives for controlling nematodes |
| JP5466842B2 (ja) * | 2008-10-29 | 2014-04-09 | ポーラ化成工業株式会社 | グルタチオン産生促進組成物 |
| US8263069B2 (en) | 2008-12-31 | 2012-09-11 | Johnson Lanny L | Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions |
| KR20100104482A (ko) * | 2009-03-18 | 2010-09-29 | 한림대학교 산학협력단 | 췌장베타세포를 보호하는 활성과 혈당조절 활성이 우수한 흑옥수수 안토시아닌（ｐｕｒｐｌｅ ｃｏｒｎ ａｎｔｈｏｃｙａｎｉｎｓ） |
| SMT202000086T1 (it) | 2010-04-12 | 2020-03-13 | Reata Pharmaceuticals Inc | Bardoxolone metile per il trattamento dell'obesità |
| US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| WO2011146768A1 (en) * | 2010-05-20 | 2011-11-24 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| JP6001060B2 (ja) * | 2011-06-06 | 2016-10-05 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 筋萎縮を阻害するための方法 |
| WO2012168108A1 (en) * | 2011-06-06 | 2012-12-13 | Unilever Plc | An edible composition |
| MX2011011881A (es) * | 2011-10-17 | 2013-04-17 | Agustin Lugo Radillo | Uso de la delfinidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes. |
| KR101406126B1 (ko) * | 2012-08-20 | 2014-06-12 | 도종묵 | 백운풀 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 |
| CA2918291C (en) | 2013-07-22 | 2022-12-06 | Universite Du Quebec A Chicoutimi | Use of plant extracts against herpes simplex virus |
| US9968623B2 (en) | 2013-08-29 | 2018-05-15 | Lanny Leo Johnson | Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent |
| JP2014040487A (ja) * | 2013-12-03 | 2014-03-06 | Kao Corp | 脂肪蓄積抑制剤 |
| JP6716468B2 (ja) | 2014-05-05 | 2020-07-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 |
| JP2014156483A (ja) * | 2014-05-23 | 2014-08-28 | Pola Chem Ind Inc | 熱産生タンパク質発現促進剤 |
| ES2570433B1 (es) * | 2014-10-17 | 2016-11-21 | Universitat Rovira I Virgili | Utilización de proantocianidinas para la supresión del apetito o inducción de la saciedad |
| CA2987143A1 (en) * | 2015-05-25 | 2016-12-01 | Arborvitae Health And Wellbeing Pty. Ltd. | Composition and uses thereof |
| EP3124047A1 (en) | 2015-07-28 | 2017-02-01 | Merz Pharma GmbH & Co. KGaA | Pentacyclic triterpenoids for injection lipolysis |
| KR102285839B1 (ko) * | 2019-03-07 | 2021-08-04 | 전남대학교 산학협력단 | 산딸나무 잎 추출물을 유효성분으로 함유하는 혈관신생 억제용 조성물 |
| KR102232867B1 (ko) * | 2019-03-07 | 2021-03-25 | 전남대학교 산학협력단 | 산딸나무 잎 추출물을 유효성분으로 함유하는 항비만 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229439A (en) * | 1977-11-21 | 1980-10-21 | Societe De Recherches Industrielles (Sori) | Method of treatment of atheroma |
| JPS55111418A (en) * | 1979-02-21 | 1980-08-28 | Santen Pharmaceut Co Ltd | Remedy for eye disease and its preparation |
| JPH09227398A (ja) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | 抗肥満剤 |
| KR100195886B1 (ko) * | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| EP0956867A1 (de) * | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus |
| CA2308981A1 (fr) * | 2000-05-17 | 2001-11-17 | Daniel Gaudet | Derives triterpeniques |
| CA2421109C (en) * | 2000-08-31 | 2011-05-03 | Hauser, Inc. | Efficient method for producing compositions enriched in anthocyanins |
| AU2000274550A1 (en) * | 2000-09-25 | 2002-04-02 | Ultimate Life Technology Co., Ltd. | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
| JP4350885B2 (ja) * | 2000-11-24 | 2009-10-21 | 均司 石田 | 内臓脂肪量抑制用組成物の製法 |
| JP2003171303A (ja) * | 2001-09-17 | 2003-06-20 | Suzuka Univ Of Medical Science | 特定植物含有組成物と該組成物を有効成分とする医薬品と保健用食品 |
| JPWO2003039270A1 (ja) * | 2001-11-08 | 2005-02-24 | 日清オイリオグループ株式会社 | 抗肥満用飲食物 |
| JP2003252766A (ja) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | シアニジン３−グルコシドを有効成分とする抗肥満及び／又は抗糖尿病剤 |
| CA2480471A1 (en) * | 2002-03-26 | 2003-10-02 | Forbes Medi-Tech Inc. | A process for the extraction of anthocyanins from black rice and composition thereof |
| US20040131749A1 (en) * | 2002-08-29 | 2004-07-08 | Archer-Daniels-Midland Company | Phytochemicals from edible bean process streams |
| EP1602652A1 (en) * | 2003-03-03 | 2005-12-07 | San-Ei Gen F.F.I., Inc. | Adiponectin expression promoter |
| CN1475222A (zh) * | 2003-07-31 | 2004-02-18 | 凯 曹 | 匙羹藤叶精提物及其制备工艺 |
| JP4451627B2 (ja) * | 2003-09-05 | 2010-04-14 | 株式会社ニチレイフーズ | 血糖値上昇抑制剤およびａｇｅ生成阻害剤 |
| JP2005097216A (ja) * | 2003-09-26 | 2005-04-14 | Kaneka Corp | ＰＰＡＲγリガンド剤 |
| CN1259068C (zh) * | 2004-04-28 | 2006-06-14 | 江苏中康新药指纹图谱开发有限公司 | 山茱萸提取物及其制备方法和用途 |
| US7772195B2 (en) * | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| US7737121B2 (en) * | 2004-07-29 | 2010-06-15 | Board Of Trustees Of Michigan State University | Insulin secretion by anthocyanins and anthocyanidins |
-
2005
- 2005-03-04 US US11/072,151 patent/US7772195B2/en not_active Expired - Fee Related
- 2005-07-25 AU AU2005285463A patent/AU2005285463B2/en not_active Ceased
- 2005-07-25 NZ NZ552395A patent/NZ552395A/en not_active IP Right Cessation
- 2005-07-25 BR BRPI0513840-0A patent/BRPI0513840A/pt not_active IP Right Cessation
- 2005-07-25 EP EP05813068A patent/EP1771188A4/en not_active Withdrawn
- 2005-07-25 MX MX2007000679A patent/MX2007000679A/es not_active Application Discontinuation
- 2005-07-25 WO PCT/US2005/026220 patent/WO2006031293A2/en not_active Ceased
- 2005-07-25 CA CA002573539A patent/CA2573539A1/en not_active Abandoned
- 2005-07-25 RU RU2007101492/15A patent/RU2359689C2/ru not_active IP Right Cessation
- 2005-07-25 JP JP2007523680A patent/JP2008508284A/ja active Pending
-
2010
- 2010-05-04 US US12/773,277 patent/US8198249B2/en not_active Expired - Fee Related
-
2012
- 2012-04-30 US US13/460,781 patent/US20120283203A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8198249B2 (en) | 2012-06-12 |
| EP1771188A2 (en) | 2007-04-11 |
| AU2005285463B2 (en) | 2008-08-21 |
| US20060025354A1 (en) | 2006-02-02 |
| WO2006031293A3 (en) | 2006-09-14 |
| US7772195B2 (en) | 2010-08-10 |
| CA2573539A1 (en) | 2006-03-23 |
| MX2007000679A (es) | 2007-03-30 |
| RU2007101492A (ru) | 2008-09-10 |
| US20120283203A1 (en) | 2012-11-08 |
| WO2006031293A8 (en) | 2007-04-05 |
| US20110003762A1 (en) | 2011-01-06 |
| AU2005285463A1 (en) | 2006-03-23 |
| RU2359689C2 (ru) | 2009-06-27 |
| NZ552395A (en) | 2009-07-31 |
| WO2006031293A2 (en) | 2006-03-23 |
| EP1771188A4 (en) | 2010-04-21 |
| JP2008508284A (ja) | 2008-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loss et al. | Artificial skin, split-thickness autograft and cultured autologous keratinocytes combined to treat a severe burn injury of 93% of TBSA | |
| Bing et al. | Randomized, multicenter, double‐blind, and placebo‐controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial‐thickness burns and skin graft donor site | |
| Adeghate et al. | Novel biological therapies for the treatment of diabetic foot ulcers | |
| Chen et al. | A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers | |
| Fan et al. | Curcumin prevents diabetic osteoporosis through promoting osteogenesis and angiogenesis coupling via NF‐κB signaling | |
| BR0011891A (pt) | Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso | |
| BRPI0510613A (pt) | cisteaminas para tratar complicações de hipercolesterolemia e diabete | |
| Nie et al. | Biological effects and clinical application of negative pressure wound therapy: a review | |
| Wang et al. | Chronic calcaneal osteomyelitis associated with soft‐tissue defect could be successfully treated with platelet‐rich plasma: a case report | |
| Jiang et al. | Advance of peripheral nerve injury repair and reconstruction | |
| Zheng et al. | Mechanical loading mitigates osteoarthritis symptoms by regulating the inflammatory microenvironment in a mouse model | |
| Zhou et al. | Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts | |
| Chen et al. | Mechanical loading modulates heterotopic ossification in calcific tendinopathy through the mTORC1 signaling pathway | |
| Chen et al. | Ultrasound-Driven selenium nanoparticles realize bone defect repair through activating selenoproteins to regulate PI3K/AKT signaling pathway | |
| Xiao et al. | Mechanical micronization of lipoaspirates combined with fractional CO2 laser for the treatment of hypertrophic scars | |
| Kumar et al. | Diabetic wound healing: navigating physiology, advancements and research frontiers | |
| Toia et al. | Microsurgery and external fixation in orthoplastic reconstruction of tibial injuries | |
| Li et al. | In-situ electrospinning dressings loaded with kaempferol for reducing MMP9 to promote diabetic ulcer healing | |
| Hong et al. | The effect of various concentrations of human recombinant epidermal growth factor on split‐thickness skin wounds | |
| BRPI0512869A (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente | |
| Coury | Expediting the transition from replacement medicine to tissue engineering | |
| Orcajo et al. | The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal perforant ulcer in the foot of a person with diabetes | |
| Xia et al. | Fabrication of waterproof, breathable composite liquid dressing and its application in diabetic skin ulcer repair | |
| WO2016090892A1 (zh) | 一种治疗糖尿病足的水溶性凝胶 | |
| Huang et al. | Rosiglitazone alleviates injury in rats with adenine-induced chronic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |